Scholar Rock Holding's 15min chart shows RSI Overbought, KDJ Death Cross signals.

Based on the 15-minute chart for Scholar Rock Holding, the RSI (Relative Strength Index) has reached an overbought level, and the KDJ (Stochastic Oscillator) has triggered a death cross on August 20, 2025 at 12:30. This suggests that the stock price has risen too quickly and is no longer supported by fundamental factors, and momentum is shifting towards the downside with potential for further decreases.

UroGen Pharma Ltd. (NASDAQ:URGN), a biopharmaceutical company focused on developing innovative therapies for urological diseases, has been under scrutiny for its financial performance. The company's Return on Invested Capital (ROIC) stands at -77.63%, while its Weighted Average Cost of Capital (WACC) is 9.28%. This results in a ROIC to WACC ratio of -8.36, indicating that UroGen is not generating sufficient returns to cover its cost of capital, highlighting inefficiencies in capital utilization [1].

Comparatively, AnaptysBio, Inc. (ANAB) shows a ROIC of -28.56% and a WACC of 13.21%, leading to a ROIC to WACC ratio of -2.16. Although negative, this ratio is less negative than UroGen's, suggesting that AnaptysBio is closer to achieving a balance between returns and capital costs [1].

Y-mAbs Therapeutics, Inc. (YMAB) and Rhythm Pharmaceuticals, Inc. (RYTM) also exhibit negative ROIC to WACC ratios of -4.27 and -4.72, respectively, indicating that both companies are struggling to generate returns that exceed their capital costs. However, their ratios are less negative than UroGen's, suggesting slightly better capital efficiency [1].

Wave Life Sciences Ltd. (WVE) and Scholar Rock Holding Corporation (SRRK) have ROIC to WACC ratios of -17.48 and -17.97, respectively. These ratios are more negative than UroGen's, suggesting even greater inefficiencies in capital utilization. Despite this, UroGen's significant negative ratio remains a critical area for improvement to enhance its financial performance [1].

In addition to the financial metrics, technical indicators also provide insights into the stock's performance. As of August 20, 2025, the RSI (Relative Strength Index) of Scholar Rock Holding (SRRK) reached an overbought level, and the KDJ (Stochastic Oscillator) triggered a death cross, suggesting that the stock price has risen too quickly and is no longer supported by fundamental factors. This momentum shift indicates potential for further decreases in the stock price [2].

References:
[1] https://site.financialmodelingprep.com/market-news/urogen-pharma-financial-performance-competitive-analysis
[2] https://site.financialmodelingprep.com/market-news/scholar-rock-holding-technical-analysis